Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naoluoxintong is a Traditional Chinese Medicine (TCM) formulation, typically administered as a granule, developed by the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine. It is primarily indicated for the treatment of ischemic stroke during the recovery period, specifically for patients presenting with the TCM syndrome of Qi deficiency and blood stasis. The formulation is designed to tonify Qi, activate blood circulation, and resolve stasis. Clinical studies, including a registered Phase 4 trial (ChiCTR-IPR-14005269), have evaluated its efficacy and safety when used in combination with standard antiplatelet therapy, such as aspirin, to improve neurological function and clinical outcomes in stroke patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Naoluoxintong.